

BRADBURY DANIEL  
Form 4  
October 23, 2008

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**BRADBURY DANIEL**

(Last) (First) (Middle)

**AMYLIN PHARMACEUTICALS  
INC, 9360 TOWNE CENTRE DR**

(Street)

**SAN DIEGO, CA 92121**

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
**ILLUMINA INC [ILMN]**

3. Date of Earliest Transaction  
(Month/Day/Year)  
**10/21/2008**

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V Amount or Price (A) or (D)			
Common Stock	10/21/2008		M	5,500 <sup>(1)</sup> A \$ 4.035	7,500 <sup>(2)</sup>	D	
Common Stock	10/21/2008		S	5,500 <sup>(1)</sup> D \$ 32.587 <sup>(3)</sup>	2,000	D	
Common Stock	10/21/2008		M	500 <sup>(1)</sup> A \$ 4.035	2,500	D	
Common Stock	10/21/2008		S	500 <sup>(1)</sup> D \$ 33.212 <sup>(4)</sup>	2,000	D	

Edgar Filing: BRADBURY DANIEL - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
*(e.g., puts, calls, warrants, options, convertible securities)*

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Security (Instr. 3 and 4)	8. Date Exercisable	9. Expiration Date	10. Title	11. Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	\$ 4.035	10/21/2008		M	5,500 (1)	01/09/2005 01/09/2014	Common Stock				5,500
Non-Qualified Stock Option (right to buy)	\$ 4.035	10/21/2008		M	500 (1)	01/09/2005 01/09/2014	Common Stock				500

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
BRADBURY DANIEL AMYLIN PHARMACEUTICALS INC 9360 TOWNE CENTRE DR SAN DIEGO, CA 92121		X		

## Signatures

Octavio Espinoza for Daniel M. Bradbury  
Date: 10/23/2008

*\*\*Signature of Reporting Person*  
*Date*

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Sale pursuant to 10(b)5-1 plan.
- (2)

## Edgar Filing: BRADBURY DANIEL - Form 4

On 9/22/08, the common stock of Illumina split two for one, resulting in the reporting person's ownership of 1,000 additional shares of stock.

- (3) Weighted average sale price representing 5,500 shares sold ranging from \$32.13 to \$33.105 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request.
- (4) Weighted average sale price representing 500 shares sold ranging from \$33.14 to \$33.38 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request.
- (5) This option was previously reported as covering 20,000 shares at an exercise price of \$8.07 per shares, and was adjusted to reflect Illumina's two for one stock split that occurred on 9/22/08.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.